ASXC

Asensus Surgical, Inc. (ASXC) | Rumor.io

Asensus Surgical

ASXC

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about ASXC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 22

Asensus Surgical, Inc. (ASXC) has been involved in a controversy surrounding its management and acquisition, with some investors accusing the company of being "exploited by a bunch of crooks" and others calling for punishment for the Board of Directors and Karl Storz.
The company's technology has been described as "fine and award-winning," but the issue lies with the company's management and the actions of its former CEO, Andrea, who bought 600k shares at $0.67 to mislead investors.
The company has been sold to Karl Storz for $0.35 per share, with some investors taking significant losses, including one who took an 85% loss and another who is calling for the Board of Directors and Karl Storz to be punished.

Generated by AI

Sentiment

Of the messages about ASXC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	0% -21.71
Bearish	—	—	—	100% +21.71

Bullish· Jun 7

The acquisition of Asensus Surgical by Karl Storz could lead to a bidding war, potentially driving up the price to $0.50 or higher.
The deal is not yet finalized, and shareholder approval is still required, which could lead to further price increases or changes in the acquisition terms.
The buyout price of $0.35 is significantly undervalued, and the company's long-term potential could be compromised if it falls into private hands without public trading options.

Bearish· Aug 14

The company's management is accused of intentionally harming shareholders with bad faith actions, leading to a potential class action lawsuit.
The current buyout offer of $0.35 per share is considered too low and a non-starter, with some investors expecting a higher offer from Stortz.
The company's bankruptcy and liquidation could result in the wiping out of carryforward shares, with some investors hoping for a chance to get some money back through a lawsuit.

Generated by AI

Topics

Of the messages about ASXC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	—
Announcements	—	—	—	—
Controversies	—	—	—	—
Earnings	—	—	—	—
Macro	—	—	—	—
Technical Analysis	—	—	—	—

Earnings· Mar 11

Asensus Surgical (ASXC) reported Q4 EPS of -$0.09, beating estimates by $0.03, and revenue of $1.11M, beating estimates by $0.14M.
The company closed two equity financings, totaling approximately $111 million in gross proceeds, extending its cash runway into 2024.
ASXC's Q4 results mark the third consecutive quarter of great momentum, with the company's recent capital raise and FDA approvals generating optimism among investors.

Analysts· May 26

HC Wainwright & Co. initiated coverage on Asensus Surgical with a Buy rating and a price target of $4.
Analyst Swayampakula Ramakanth expects Asensus Surgical to see continued momentum in 2021, with the company installing up to 12 new Senhance systems by the end of the year.
Asensus Surgical's shares surged 27% in afternoon trading following H.C. Wainwright's initiation, with some analysts predicting a price range of $4-10.

Announcements· Sep 7

Asensus Surgical, Inc. (ASXC) has partnered with NVIDIA to enhance augmented intelligence capabilities of its ISU.
The collaboration aims to jointly develop and commercialize digital surgical solutions, with both companies gaining early access to relevant product roadmaps.
The partnership may lead to innovative business models for the development, deployment, and commercialization of digital surgical solutions.

Technical Analysis· May 26

$ASXC has a key indicator for a more significant uptrend at $2.94 and confirmation of an uptrend at $3.01.
The 50ema is a crucial level for $ASXC, and a break above it could lead to further gains.
$ASXC has a potential breakout wedge on the 4hr chart, and a successful breakout could lead to a significant price increase.

Generated by AI

Community

Of the messages about ASXC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	60.87%
Newcomers	—	—	—	39.13%

Regulars· Feb 21

$ASXC Asensus Surgical Inc. shares have been halted due to a corporate update, which may be related to investor day announcements.
Asensus Surgical Inc. has resumed trading after a halt, with a 5.9% increase in the last 20 minutes, and a 10.25% increase in the last 6 minutes.
Asensus Surgical Inc. has filed an SEC Form 8-K, disclosing a corporate update, including Regulation FD Disclosure and other events, which may have contributed to the stock's volatility.

Newcomers· Sep 7

The collaboration between Asensus Surgical, Inc. ($ASXC) and NVIDIA ($NVDA) is driving the stock's price up, with some users expecting a potential price of $0.50.
Newcomers are focused on the potential of the $ASXC stock to bounce off the 20sma/5min and show strong momentum, with some users already seeing a surge in price.
The partnership between $ASXC and $NVDA is being viewed as a strong watch, with users keeping a close eye on the stock's price and potential for a significant increase.

Generated by AI

Also Discussed

Investors talking about ASXC also mention

#	Name	Attention
1	Intuitive Surgical Inc.ISRG	0%0
2	TRVN - Trevena, Inc.	——
3	Medtronic plcMDT	0%+0
4	Stryker CorporationSYK	0.01%+0.01
5	Vicarious Surgical Inc.RBOT	0%new
6	Senseonics Holdings, Inc.SENS	0%+0
7	Ekso Bionics Holdings, Inc.EKSO	0%new
8	Bionano Genomics Inc.BNGO	0%0
9	Verastem Inc.VSTM	0%0
10	CareCloud Inc.CCLD	0%new